- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Press Release
ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
Published: Feb 4, 2015 6:00 a.m. ET
Receives Notice of Allowance for Composition of Matter Patent Extending Exclusivity Coverage to at least 2031
EDISON, N.J., Feb. 4, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. CTRV, -15.85% a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, "Nucleoside Phosphonate Salts." The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031.
"This Notice of Allowance is a significant development for ContraVir, as it inherently increases the value of CMX157, allowing us the added time to expand the potential for this asset," said James Sapirstein, Chief Executive Officer of ContraVir. "The extended patent life also provides additional flexibility for the Company to pursue different combination therapies, as well as new development pathways for CMX157. We are looking to position ContraVir as a leader in the HBV space, an area that is poised for substantial further growth."
CMX157 is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. Its novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. A completed Phase 1 clinical trial in healthy volunteers, demonstrated a favorable safety, tolerability and drug distribution profile. In vitro, CMX157 is highly active against HBV and was more than 200-fold more potent as compared to tenofovir against all major HIV subtypes resistant to current therapies. ContraVir licensed CMX157 through a strategic collaboration with Chimerix, Inc. CMRX, -0.02% in December 2014.
About ContraVir Pharmaceuticals ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV). In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®). CMX157 is active against HBV and more than 200-fold more potent in vitro versus tenofovir against all major HIV subtypes resistant to current therapies. CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. ContraVir intends to develop CMX157 for HBV and HIV in Phase 2 clinical studies.
|
|